Cardiovascular Drug Approval Rate in the US Fell as Development Time Rose
BOSTON - Sept. 12, 2017 - Although the rate at which investigational drugs received marketing approval in the United States has declined in recent years, the cardiovascular approval rate trailed other drug approvals as a whole, while the time needed to develop cardiovascular drugs rose, according to a recently completed study conducted by the Tufts Center for the Study of Drug Development.
Approval success rates for cardiovascular compounds fell from about 5.2% for compounds that began clinical testing during 1995-00, to about 2.2% for those that started trials during 2001-07, a 58% decline, according to the study. That compares to a decline from 13.9% to 12.9% for non-cardiovascular compounds.
During the same period, mean clinical development time for cardiovascular drug approvals lengthened nearly two years from 1999-04 to 2005-10, and increased another 7% from 2005-10 to 2011-16.
Those trends together accounted for a drop of cardiovascular products as a share of new drug approvals in the U.S. According to Tufts CSDD, new cardiovascular drugs accounted for 27% of all U.S. new drug approvals in the 1980s, but only 13% during 2010-16.
The findings were reported in the September/October Tufts CSDD Impact Report, released September 12.
"Demand for new cardiovascular drugs will continue, but developers seem to be shifting investments to other therapeutic areas, in part, in response to lengthening development times and lower approval rates associated with cardiovascular products," noted Joseph A. DiMasi, director of economic analysis at Tufts CSDD and the study's author.
He said rising development costs and regulatory uncertainty are among the factors that have increased development challenges for cardiovascular drugs.
Other findings from the study include the following:
- The overall clinical approval success rate for cardiovascular drugs first tested in human subjects from 1995 to 2007 was 3.7%, or less than one-third the 12.9% rate for non-cardiovascular drugs.
- Fewer new cardiovascular drugs received a priority rating compared to other drugs approved during 1999-16 (38% vs. 50%).
- During 1999-16, mean approval phase time for cardiovascular drug approvals was 17.5 months, or 22%, longer than the 14.3 months for non-cardiovascular approvals.
ABOUT THE TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT
The Tufts Center for the Study of Drug Development at Tufts University provides strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of pharmaceutical development, review, and utilization. Tufts CSDD, based in Boston, conducts a wide range of in-depth analyses on pharmaceutical issues and hosts symposia, workshops, and public forums, and publishes Tufts CSDD Impact Reports, a bi-monthly newsletter providing analysis and insight into critical drug development issues.
Contacts:
Tufts Center for the Study of Drug Development
Rachel Stanton | 617-636-2170 | csdd@tufts.edu
Business Communication Strategies
Peter Lowy | 617-734-9980 | lowy@bus-com.com
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
